Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONQUEST platform trial in systemic sclerosis-associated interstitial lung disease
MOH_2024-08-06_013566Phase 2Not yet recruiting
- Sponsor
- Scleroderma Research Foundation
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) comparing Amlitelimab substudy arm with BI 1015550 substudy arm (2 arms). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
amlitelimabnerandomilast
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on MOH_2024-08-06_013566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-06_013566.